On November 2, 2016 Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion protein, from dose escalation into Phase 1b cohort expansion enrollment in patients with advanced hematologic malignancies (Filing, 6-K, Trillium Therapeutics, NOV 2, 2016, View Source [SID1234516179]). As part of the advancement, the company provides the following study updates: Schedule your 30 min Free 1stOncology Demo! Trillium has completed a dose-escalation phase of TTI-621 in patients with lymphoma, and will report interim Phase 1a data at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Patient enrollment across a broad spectrum of hematologic malignancies has commenced in the Phase 1b multi-cohort expansion portion of the trial. The trial’s objectives are to further characterize the safety of TTI-621 and gain preliminary evidence of anti-tumor activity in patients with a variety of hematologic malignancies.
In addition to the eight original expansion cohorts, indolent B cell lymphoma, aggressive B cell lymphoma, T cell lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, multiple myeloma, acute myeloid leukemia and myelodysplastic syndrome, the phase 1b expansion will also include patients with myeloproliferative neoplasms.
In a separate expansion cohort, patients with CD20-positive lymphomas will be treated with TTI-621 in combination with rituximab.
The Phase 1b enrollment will engage multiple new clinical trial sites, in addition to the existing five participating in Phase 1a.
"TTI-621 is a decoy receptor that blocks CD47 — a ‘do not eat’ signal that is a key regulator of innate and adaptive immunity," commented Trillium’s Chief Medical Officer, Eric Sievers, MD. "Having established a well-tolerated dose and schedule of TTI-621, we are enthusiastic to characterize safety and anti-tumor activity across multiple blood cancers. In addition, we look forward to evaluating TTI-621 in combination with rituximab."